Johnson & Johnson
NYSE:JNJDrug Manufacturers - General
-$4.59 today
- Market cap
- $656.47B
- Beta
- 0.26
- P/E (TTM)
- 26.7
- EPS (TTM)
- $8.60
- Dividend yield
- 2.28%
Volume 7.93M
Average 7.71M
JNJ EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Johnson & JohnsonNYSE: JNJ
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA declines year over year
Q3 FY2026 EBITDA of $6.37B fell 31.5% year over year, behind the -22.1% change in trailing-twelve-month EBITDA. Sequentially, it fell 29.2% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.
Context
- EBITDA amounted to 43.6% of revenue in FY2025, up 15.7 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 16 analysts of $37.42B (-8.9%) for the fiscal year ending Dec 2026, a slowdown from the +65.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $6.37B-29.2% QoQ
- Last fiscal yearDec 2025
- $41.06B+65.7% YoY
- LTMSep 2026
- $30.81B-22.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -31.5% | +40.4% | +71.9 pp |
| 1 year | +65.7% | -8.9% | -74.5 pp |
| 3-year CAGR | +15.6% | +2.3% | -13.2 pp |
| 5-year CAGR | +5.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 41.06B USD
- Year-over-year change
- +65.7%
- 4-year CAGR
- +11.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 41.06B | +65.7% |
| FY2024 | 2024-12-29 | 24.78B | +6.3% |
| FY2023 | 2023-12-31 | 23.32B | -12.3% |
| FY2022 | 2023-01-01 | 26.61B | -0.5% |
| FY2021 | 2022-01-02 | 26.75B | — |
EBITDA vs competitors
How JNJ compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -22.1% is the 8th highest of 11, against a peer median of +6.5%.
- EBITDA amounts to 31.0% of revenue for JNJ, versus a peer median of 32.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $30.81B USD | -22.1% | +15.6% | 31.0% | |
| LTM Sep 2026 | $24.15B USD | +88.7% | -10.0% | 36.6% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B USD | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | $16.82B USD | +11.6% | -7.5% | 34.2% | |
| LTM Jun 2026 | €14.77B EUR | +15.5% | -2.6% | 30.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | £8.8B GBP | +2.2% | +6.5% | 26.5% | |
| LTM Jun 2026 | $1.33B USD | -87.8% | +15.3% | 4.4% | |
| Peer median (excluding JNJ) | — | +6.5% | +8.2% | 32.2% | |
Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.74B | 79.99B | 85.16B | 88.82B | 94.19B |
| Cost of Revenue | 23.4B | 24.6B | 26.55B | 27.47B | 30.26B |
| Gross Profit | 55.34B | 55.39B | 58.61B | 61.35B | 63.94B |
| Gross Margin | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Research & Development | 14.28B | 14.14B | 15.09B | 17.23B | 14.67B |
| Selling, General & Admin | 20.12B | 20.25B | 20.11B | 21.97B | 23.68B |
| Operating Expenses | 34.4B | 34.38B | 35.2B | 39.2B | 38.34B |
| Depreciation & Amortization | 7.39B | 6.97B | 7.49B | 7.34B | 7.5B |
| EBITDA | 26.75B | 26.61B | 23.32B | 24.78B | 41.06B |
| EBITDA Margin | 34.0% | 33.3% | 27.4% | 27.9% | 43.6% |
| Operating Income | 20.94B | 21.01B | 23.41B | 22.15B | 25.6B |
| Operating Margin | 26.6% | 26.3% | 27.5% | 24.9% | 27.2% |
| Interest Income | 53M | 490M | 1.26B | 1.33B | 1.06B |
| Interest Expense | 183M | 276M | 772M | 755M | 971M |
| Other Income / Expenses | (1.77B) | (1.65B) | (8.35B) | (5.46B) | 6.99B |
| Income Before Tax | 19.18B | 19.36B | 15.06B | 16.69B | 32.58B |
| Pre-Tax Margin | 24.4% | 24.2% | 17.7% | 18.8% | 34.6% |
| Income Tax Expense | 1.38B | 2.99B | 1.74B | 2.62B | 5.78B |
| Net Income | 20.88B | 17.94B | 35.15B | 14.07B | 26.8B |
| Net Margin | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| EPS (Basic) | 7.93 | 6.83 | 13.88 | 5.84 | 11.03 |
| EPS (Diluted) | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 |
| Weighted Avg Shares | 2.63B | 2.61B | 2.53B | 2.41B | 2.43B |
| Weighted Avg Shares (Diluted) | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B |
Johnson & Johnson
NYSE:JNJ
Intrinsic Alpha fair value
Locked
Current Price
$272.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.